Peritoneal carcinomatosis (PC) is a condition where cancer cells spread from internal organ tumors, significantly invading the abdominal and pelvic lining.

Typically diagnosed at an advanced stage, PC complicates treatment options, and the median survival for gastric cancer patients with PC is around four to six months.

For most patients, PC indicates a limited prognosis of only a few months, with current treatments primarily focused on palliative care.

Prostate cancer, the second most common cancer in males, often leads to castration-resistant prostate cancer (CRPC) due to the development of resistance against androgen deprivation therapy.

CRPC arises when androgen receptor (AR) signaling becomes independent of androgens, often due to mutations or amplifications in the AR gene.

Nuclear hormone receptors (NHRs), including AR, play a crucial role in regulating gene expression and have implications for prostate cancer treatment.

A deeper understanding of NHR interactions may lead to novel therapeutic approaches for advanced prostate cancer.

Specific long non-coding RNAs (lncRNAs), such as HOTAIR and MALAT1, have been identified as key players in cancer progression, correlating with poor outcomes in prostate cancer patients.

Research into lncRNAs highlights their significant influence on lipid levels, metabolism, and cardiovascular disease risk, suggesting their potential as therapeutic targets and biomarkers.

Reverse cholesterol transport (RCT) is crucial for maintaining low circulating cholesterol levels, thereby reducing cardiovascular disease risk.

Cardiovascular disease remains a leading cause of mortality, with approximately 17.9 million deaths annually linked to lifestyle choices and genetic factors.

Despite a growing body of work on non-coding RNAs in other cancers, research into their role in peritoneal carcinomatosis is still in its infancy.